达塔% % 0期刊文章%格拉。一个马可Battaglini %格雷戈里·斯科特% Ozgur Yaldizli %安德烈Santos-Ribeiro % Eugenii拉宾%罗杰·甘恩%大卫欧文%一个奥尔加Ciccarelli奥马尔·马利克% %一个黎明兰登理查德·尼古拉斯% %尼古拉·德·斯特凡诺% Paul Matthews % T皮质c [11] PBR28宠物小胶质炎症指标解释认知能力差异的女士(S41.005) % D J神经病学2016% % P S41.005 X % V % 86% N 16补充目的:描述先天大脑MRI炎症反应的关系标记病理学和残疾的多发性硬化症(MS)。首页背景:慢性小胶质激活导致神经退化在女士我们使用c [11] PBR28宠物评估激活小胶质负担方法:女士24女士志愿者(17 RR: 7 SP MS)和11个健康志愿者接受了PET扫描和c [11] PBR28 3 t磁共振成像。在女士,T2白质病变(WML), DIR皮质病变(CL)和正常白质(NAWM) MRI分割。c [11] PBR28分布体积比(DVR)估计洛根图解法和尾参考区域。正常化通用卷计算使用SIENAX(目前工具箱)。残疾是评估使用eds和简短的国际认知评估女士(BICAMS)电池。NAWM结果:意思是DVR(意思是+ / - SD, 1.27 + / - 0.25)大于WML(1.03 + / - 0.26)和WM健康对照组(0.99 + / - 0.13,与p < 4 x10-4)。之间没有区别病人女士生皮质DVR(1.41 + / - 0.20)和控制(1.33 + / - 0.17,p = 0.284),但患者更高的皮质DVR女士当正常皮质体积(0.25 + / - 0.06和0.21 + / - 0.04,p < 0.05)。BICAMS和eds相关整个通用卷(枪兵的ρ= 0.45,p = 0.028和ρ= -0.41,p = 0.049)。eds并不与c [11] PBR28吸收。 However, BICAMS was correlated to DVR in cortex (rho = -0.432, p = 0.035) and in CL (rho = -0.50, p = 0.013) and to cortical DVR normalised to cortical volume (rho = - 0.42, p = 0.041) Conclusions: [11C]PBR28 highlights a correlation of microglial inflammation in whole cortex and CL to cognitive impairment in MS. Diffuse innate immune activation may explain aspects of disability not well accounted for by T2 lesion load.Disclosure: Dr. Datta has received research support from GlaxoSmithKline. Dr. Battaglini has nothing to disclose. Dr. Scott has nothing to disclose. Dr. Yaldizli has received personal compensation for activities with Teva and Bayer Schering as a speaker. Dr. Santos-Ribeiro has nothing to disclose. Dr. Rabiner has received personal compensation for activities with GSK, BioTie, Gedeon Richter, Teva Neuroscience, and Lighlake Therapeutics as a consultant and speaker. Dr. Rabiner has received research support from Abbvie. Dr. Rabiner holds stock and/or Dr. Gunn has received personal compensation from GlaxoSmithKline, Abbvie, UCB Pharma and ITI as a consultant. Dr. Owen has nothing to disclose. Dr. Malik has received personal compensation for activities with Biogen Idec, Novartis, and Merck/Serono. Dr. Ciccarelli has received personal compensation for activities with Novartis, Biogen and GE as a consultant. Dr. St. John Nicholas has received personal compensation for activities with Bayer Pharmaceuticals Corporation as a speaker, and Biogen Idec as a principal investigator, researcher, speaker and for serving on the advisory board. Dr. Landgon has receiverd personal compensation for activities with Bayer Schering Pharma AG/Bayer HealthCare Pharmaceuticals, Biogen, and Hoffman. Dr. De Stefano has received personal compensation for activities with Schering, Biogen Idec, Teva, Novartis, Genzyme, and Merk Serono S.A. for consulting services, speaking and travel support and for activities with Merk Serono S.A. as an advisory board m Dr. Matthews has received personal compensation for activities with Biogen, Novartis, Ixico, transparency Life Sciences, and Adelphi Communications. Dr. Matthews has received research support from GlaxoSmithKline and Biogen.Wednesday, April 20 2016, 1:00 pm-3:00 pm %U